RCT | Rogaratinib vs. chemotherapy in patients with advancer urothelial carcinoma selected based on FGFR1/3 mRNA expression.

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression – Journal of Clinical Oncology

Commentary: Rogaratinib Is Noninferior to Chemo in Pretreated FGFR1/3 mRNA+ Locally Advanced or Metastatic Urothelial Carcinoma – OncLive

Commentary on Twitter

? FORT-1: Rogaratinib achieves similar response and overall survival as standard chemotherapy in patients with locally advanced or metastatic #UrothelialCarcinoma selected based on FGFR1/3 mRNA expression ? https://t.co/5KAIGpCSt6 #JCO #kcsm #blcsm @cnsternberg pic.twitter.com/jDfVzfwr4e

— Journal of Clinical Oncology (@JCO_ASCO) October 31, 2022